BERWYN, PA — Amring Pharmaceuticals Inc., a subsidiary of Nordic Group B.V. (Nordic Pharma), has announced the appointment of leading ophthalmologist Dr. Eric D. Donnenfeld as Chair of its U.S. Medical Advisory Board (MAB). This announcement comes as Nordic Pharma gears up to launch its innovative therapy for Dry Eye Disease, LACRIFILL® canalicular gel.
Dr. Donnenfeld, who brings over three decades of clinical experience in refractive, cornea, and cataract surgery, joins a distinguished team on the MAB that includes top-notch experts from across the country. The board will be instrumental in guiding the company’s strategy as it prepares to introduce LACRIFILL to the market.
LACRIFILL, an FDA-cleared hyaluronic acid derivative, is designed to temporarily obstruct tear drainage by blocking the canalicular system. This novel approach offers a potential game-changer in the treatment of Dry Eye Disease, a prevalent condition affecting millions of Americans.
“Nordic Pharma continues to build a world-class group of key opinion leaders with Eric agreeing to lead our esteemed MAB in the U.S.,” said Philip Gioia, President of the U.S. team poised to launch LACRIFILL under the Nordic Pharma brand. “He brings invaluable insights for developing physician-led strategies, enhancing the patient experience, and phase IV study initiatives.”
Dr. Jai G. Parekh, Chief Commercial Officer of Nordic Pharma Eye Care U.S., echoed these sentiments, lauding Dr. Donnenfeld’s track record in successful product launches in eye care. “Our team looks forward to collaborating with him. He will be instrumental in guiding us during LACRIFILL’s introduction to eye care providers and patients.”
Dr. Donnenfeld expressed his enthusiasm about the upcoming launch, describing LACRIFILL as a disruptive technology that will change the practice of ophthalmology and optometry.
In addition to Dr. Donnenfeld’s appointment, Nordic Pharma has accepted an invitation to join the American-European Congress of Ophthalmic Surgery (AECOS) and will feature prominently at the AECOS Winter Symposium this week. Dr. Vance Thompson, another member of the MAB, will present the benefits of LACRIFILL to physicians and leaders in ophthalmology and discuss select pre-order opportunities.
With this strategic appointment and the impending launch of LACRIFILL, Nordic Pharma is positioning itself as a key player in the eye care market. The company’s commitment to innovation, coupled with the expertise of its newly appointed MAB Chair, signals a promising future for those suffering from Dry Eye Disease.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.